Payment overview · 2025
General Payments
$543.49
25 reported records · 12 companies
Healthcare provider profile · identity verified
Joseph C. Millin, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SARASOTA, FL · NPI 1760484158
Verified facts
What the public records show
CMS Open Payments records show Joseph C. Millin, D.O. received $543.49 in general payments during 2025 across 25 reported records.
Novartis Pharmaceuticals Corporation accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $137.96 | 25.4% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $80.29 | 14.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $75.98 | 14.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.59 | 13.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.23 | 6.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.40 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.00 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.37 | 3.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.71 | 3.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.45 | 3.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.08 | 3.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.43 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $543.49 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $137.96 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $80.29 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $75.98 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.51 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 164 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 999 | 294 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 960 | 279 |
| Levothyroxine Sodium | Levothyroxine Sodium | 897 | 230 |
| Atorvastatin Calcium | Atorvastatin Calcium | 892 | 250 |
| Lisinopril | Lisinopril | 754 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 740 | 205 |
| Losartan Potassium | Losartan Potassium | 528 | 141 |
| Metformin Hcl | Metformin Hcl | 510 | 138 |
| Famotidine | Famotidine | 371 | 113 |
| Omeprazole | Omeprazole | 359 | 105 |
| Tramadol Hcl | Tramadol Hcl | 346 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 324 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 305 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 277 | 74 |
| Gabapentin | Gabapentin | 269 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 265 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 216 | 60 |
| Alprazolam | Alprazolam | 211 | 38 |
| Carvedilol | Carvedilol | 196 | 55 |
| Alendronate Sodium | Alendronate Sodium | 186 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 184 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 37 |
| Allopurinol | Allopurinol | 172 | 45 |
| Eliquis | Apixaban | 164 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 163 | 42 |
| Methylprednisolone | Methylprednisolone | 163 | 124 |
| Glimepiride | Glimepiride | 162 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 49 |
| Furosemide | Furosemide | 151 | 41 |
| Celecoxib | Celecoxib | 147 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 45 |
| Trazodone Hcl | Trazodone Hcl | 146 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 143 | 35 |
| Temazepam | Temazepam | 129 | 17 |
| Azithromycin | Azithromycin | 128 | 104 |
| Sertraline Hcl | Sertraline Hcl | 127 | 36 |
| Montelukast Sodium | Montelukast Sodium | 126 | 33 |
| Pregabalin | Pregabalin | 123 | 38 |
| Finasteride | Finasteride | 113 | 29 |
| Meloxicam | Meloxicam | 113 | 33 |
| Terazosin Hcl | Terazosin Hcl | 106 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 100 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 99 | 30 |
| Oxybutynin Chloride | Oxybutynin Chloride | 95 | 27 |
| Mirtazapine | Mirtazapine | 94 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 23 |
| Atenolol | Atenolol | 92 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 33 |
| Lorazepam | Lorazepam | 84 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 17 |
| Farxiga | Dapagliflozin Propanediol | 81 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 66 |
| Glipizide | Glipizide | 76 | 22 |
| Jardiance | Empagliflozin | 76 | 21 |
| Clonidine Hcl | Clonidine Hcl | 70 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 30 |
| Clonazepam | Clonazepam | 67 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 65 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | 18 |
| Propranolol Hcl | Propranolol Hcl | 64 | 15 |
| Januvia | Sitagliptin Phosphate | 62 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 44 |
| Fenofibrate | Fenofibrate | 61 | 16 |
| Nifedipine Er | Nifedipine | 60 | 16 |
| Spironolactone | Spironolactone | 60 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 16 |
| Baclofen | Baclofen | 55 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 53 | 12 |
| Simvastatin | Simvastatin | 53 | 13 |
| Synthroid | Levothyroxine Sodium | 53 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 21 |
| Myrbetriq | Mirabegron | 51 | 17 |
| Potassium Chloride | Potassium Chloride | 51 | 12 |
| Cefuroxime | Cefuroxime Axetil | 50 | 43 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | 12 |
| Donepezil Hcl | Donepezil Hcl | 46 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 17 |
| Risperidone | Risperidone | 45 | suppressed |
| Topiramate | Topiramate | 44 | 12 |
| Diazepam | Diazepam | 43 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 42 | 33 |
| Memantine Hcl | Memantine Hcl | 42 | 12 |
| Lovastatin | Lovastatin | 40 | 12 |
| Cilostazol | Cilostazol | 39 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 12 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 21 |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Ciclopirox | Ciclopirox | 34 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 28 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 12 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Primidone | Primidone | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Cephalexin | Cephalexin | 15 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Paliperidone Er | Paliperidone | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $543.49 · 25 records | Novartis Pharmaceuticals Corporation | BREZTRI, Dexcom G6 Transmitter, ELIQUIS, GEMTESA, KISUNLA, LEQVIO, NEXLETOL, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, VYEPTI, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error